

Rosina Rp Paterra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2246078/publications.pdf>

Version: 2024-02-01

18
papers

788
citations

840776

11
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

1626
citing authors

#	ARTICLE	IF	CITATIONS
1	High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 831-842.	4.2	20
2	In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. <i>Neurological Sciences</i> , 2020, 41, 347-355.	1.9	12
3	Simultaneous Detection of NF1, SPRED1, LZTR1, and NF2 Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients. <i>Genes</i> , 2020, 11, 671.	2.4	5
4	Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. <i>Neuro-Oncology</i> , 2020, 22, 1614-1624.	1.2	41
5	The Search for Molecular Markers in a Gene-Orphan Case Study of a Pediatric Spinal Cord Pilocytic Astrocytoma. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 117-130.	2.0	6
6	Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series. <i>Neurological Sciences</i> , 2020, 41, 2111-2120.	1.9	2
7	Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz022.	0.7	16
8	ABCC3 Expressed by CD56dim CD16+ NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5886.	4.1	17
9	P14.74 Remarkable response to Combined BRAF and MEK Inhibitors in two Adults with leptomeningeal carcinomatosis secondary to Pleomorphic Xanthoastrocytoma grade II with BRAFv600E mutation. <i>Neuro-Oncology</i> , 2019, 21, iii85-iii85.	1.2	0
10	Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 ⁺ T cell activation in the presence of adjuvant temozolomide. <i>Oncotarget</i> , 2018, 7, e1412901.	4.6	54
11	PATH-31. GIANT CELL GLIOBLASTOMAS: ANALYSIS OF MISMATCH-REPAIR (MMR) PROTEINS EXPRESSION, POLYMERASE Î (POLE) MUTATIONS AND THEIR ROLE IN TUMOR IMMUNORESPONSE. <i>Neuro-Oncology</i> , 2018, 20, vi165-vi165.	1.2	1
12	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 3307-3317.	7.0	230
13	Can Diffusion and Perfusion Weighted Imaging predict 1p/19q codeled lower grade gliomas?. <i>Journal of Clinical Oncology</i> , 2015, 33, 2056-2056.	1.6	0
14	TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. <i>British Journal of Cancer</i> , 2014, 111, 2024-2032.	6.4	158
15	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. <i>Neurology</i> , 2014, 83, 1200-1206.	1.1	176
16	An autoinflammatory neurological disease due to interleukin 6 hypersecretion. <i>Journal of Neuroinflammation</i> , 2013, 10, 29.	7.2	11
17	FABP4 is a candidate marker of cerebellar liponeurocytomas. <i>Journal of Neuro-Oncology</i> , 2012, 108, 513-519.	2.9	25
18	Expression profile of frizzled receptors in human medulloblastomas. <i>Journal of Neuro-Oncology</i> , 2012, 106, 271-280.	2.9	14